Idioma:

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix

COLEMAN, R. E ; HARPER, P. G ; WILTSHAW, E ; GALLAGHER, C ; OSBORNE, R ; RANKIN, E. M ; SILVERSTONE, A. C ; SLEVIN, M. L ; SOUHAMI, R. L ; TOBIAS, J. S ; TRASK, C. W

Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (3), p.280-283 [Periódico revisado por pares]

Berlin: Springer

Texto completo disponível

Citações Citado por

Enviar para

Título:
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix
Autor: COLEMAN, R. E ; HARPER, P. G ; WILTSHAW, E ; GALLAGHER, C ; OSBORNE, R ; RANKIN, E. M ; SILVERSTONE, A. C ; SLEVIN, M. L ; SOUHAMI, R. L ; TOBIAS, J. S ; TRASK, C. W
Assuntos: Adenocarcinoma - drug therapy ; Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Carcinoma, Squamous Cell - drug therapy ; Chemotherapy ; Drug Evaluation ; Female ; Humans ; Ifosfamide - administration & dosage ; Ifosfamide - adverse effects ; Ifosfamide - therapeutic use ; Infusions, Intravenous ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recurrence ; Uterine Cervical Neoplasms - drug therapy
É parte de: Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (3), p.280-283
Descrição: Forty-one patients with advanced progressing carcinoma of the cervix were treated with ifosfamide 1.5 g/m2 daily in a 30-min infusion for 5 days every 3 weeks. The overall response rate (complete + partial) was 12/39 (31%), or 12/30 (40%) in those who had not received previous chemotherapy. Six patients achieved a complete remission of disease and four of these remain disease-free 24-39 months later. Durable response were seen in patients with disease progressing after radical radiotherapy. Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients. Nausea and vomiting was experienced by all patients at some time during therapy and all patients developed alopecia. Mild neurological toxicity occurred in seven patients but severe life-threatening neurotoxicity was not seen with this schedule of administration. Further studies are needed to identify the optimum dose and schedule of ifosfamide and to ascertain its place in combination therapy.
Editor: Berlin: Springer
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix

COLEMAN, R. E ; HARPER, P. G ; WILTSHAW, E ; GALLAGHER, C ; OSBORNE, R ; RANKIN, E. M ; SILVERSTONE, A. C ; SLEVIN, M. L ; SOUHAMI, R. L ; TOBIAS, J. S ; TRASK, C. W

Berlin: Springer

Buscando em bases de dados remotas. Favor aguardar.